['neurotoxicity']
['placebo', 'gm', 'oxaliplatin-based chemotherapy']

        Inclusion Criteria:

          1. Patients shall have normal organic function such as liver function, Cardiac function
             and renal function;

          2. male or female age >18 years old;

          3. diagnosis GI cancer with histology;

          4. Chronic neurotoxicity grade is 2 or more

          5. Karnofsky Performance scores should be 80 or more

          6. patients are in oxaliplatin-based chemotherapy courses or no more than 21 days after
             last oxaliplatin usage for patients who will discontinue oxaliplatin usage.

          7. without uncured tumor except GI cancer,

          8. Patients should be expected to live no shorter than 3 months

        Exclusion Criteria:

          1. patients who is receiving anti-neurotoxicity treatment;

          2. WBC<4.0×109/L，ANC<1.5×109/L,PLT<100×109/L，Hb<90g/L,TBIL>1.5Limitation;BUN）>1.5Limitati
             on；Cr）>1.5Limitation；ALT or AST>2.5Limitation（without liver metastasis）；ALT or
             AST）>5Limitation（with liver metastasis）;

          3. heart dysfunction;

          4. brain metastasis with symptoms;

          5. peripheral nervous system or central nervous system abnormal including diabetes
             mellitus patients with neuropathy;

          6. in situation of oxaliplatin-based chemotherapy progressed, the next chemotherapy
             regime should not contain agents which will cause neurotoxicity (such as paclitaxel
             and cisplatin)
      